Serum Biomarkers Predict TNF Inhibitor Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of reliable predictive biomarkers for therapeutic response to TNF inhibitor therapy in rheumatoid arthritis patients, making it challenging to determine which patients will benefit from this treatment.
Innovation Solution
Elevated baseline levels of serum biomarkers CXCL10, CXCL13, and sCD27 are used to predict a favorable response to TNF inhibitor therapy, with methods involving biological sample analysis and comparison to reference levels to guide treatment decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TNF inhibitor therapy is administered to rheumatoid arthritis patients, then treatment effectiveness may be improved, but without reliable predictive biomarkers, it is difficult to identify which patients will respond favorably, leading to potential treatment failure or inappropriate treatment selection
Solution Approach 1:
The patent measures biomarker levels (CXCL10, CXCL13, sCD27) in the baseline serum sample obtained before TNF inhibitor therapy is initiated. This preliminary measurement allows prediction of therapeutic response before treatment begins, enabling clinicians to identify patients who are most likely to respond favorably to TNF inhibitor therapy, thereby resolving the contradiction between improving treatment selection accuracy and the lack of predictive information.
2Measurement precision
If serum biomarker testing is performed to predict therapeutic response, then treatment selection accuracy is improved, but additional diagnostic steps and resources are required
Solution Approach 1:
The patent focuses on measuring specific biomarker parameters (CXCL10, CXCL13, sCD27) in serum samples rather than performing comprehensive diagnostic workups. By concentrating on these three specific parameters that have been identified as predictive of TNF inhibitor response, the approach achieves accurate treatment prediction while minimizing the complexity of the diagnostic testing procedure.
3Productivity
If baseline biomarker levels are measured to guide treatment decisions, then therapeutic efficacy can be optimized, but treatment timing and decision-making complexity increase
Solution Approach 1:
The patent performs biomarker measurement in the baseline serum sample obtained at the time of treatment initiation, before TNF inhibitor therapy begins. This preliminary assessment allows treatment decisions to be made based on predictive biomarker data without delaying the start of therapy, as the biomarker measurement can be performed on the baseline sample that would otherwise be discarded or stored. This resolves the contradiction between optimizing treatment effectiveness through biomarker-guided decisions and the time required for assessment.
Data Source
AI summary
The present disclosure is directed to methods and kits for using serum biomarkers, including C-X-C Motif Chemokine Ligand 10 (CXCL10), C-X-C Motif Chemokine Ligand 13 (CXCL13), and/or soluble CD27 (sCD27), in predicting and evaluating therapeutic response to Tumor Necrosis Factor (TNF) inhibitor therapy in a patient in need thereof.